Back to Search Start Over

Association of gene mutations with clinicopathologic features in patients with external auditory canal squamous cell carcinoma

Authors :
Morita, Shinya
1000000374421
Kano, Satoshi
Hatanaka, Kanako C.
Hatanaka, Yutaka
Suzuki, Takayoshi
Fukuda, Atsushi
Hoshino, Kimiko
Fujiwara, Keishi
1000020344509
Nakamaru, Yuji
1000030312359
Homma, Akihiro
Morita, Shinya
1000000374421
Kano, Satoshi
Hatanaka, Kanako C.
Hatanaka, Yutaka
Suzuki, Takayoshi
Fukuda, Atsushi
Hoshino, Kimiko
Fujiwara, Keishi
1000020344509
Nakamaru, Yuji
1000030312359
Homma, Akihiro
Publication Year :
2022

Abstract

Background External auditory canal squamous cell carcinoma (EACSCC) is a rare form of malignant tumor. Due to the extremely limited understanding of the genomic landscape in EACSCC, the association between gene mutations and clinicopathologic features remains unclear. This study aimed to explore somatic gene mutations associated with the clinicopathological features in patients with EACSCC, and to identify the candidate gene mutations for predicting survival outcome in EACSCC. Methods Twenty-two tissue samples obtained from patients with EACSCC were analyzed for genetic mutations based on targeted next-generation sequencing and genetic expression based on IHC staining to investigate the driver of tumorigenesis and/or the candidates of genes for predicting clinical outcome in EACSCC. Results Gene alterations were most frequently observed in TP53 (59.1%), followed by CREBBP (9.1%). TP53 mutations showed significant correlation with T classification (P = 0.027) and p53 expression phenotype (P < 0.001). The 5-year overall survival (OS) rates for EACSCC patients with TP53 mutations and wild-type TP53 were 45.0% and 75.0%, respectively. Multivariable analysis using the Cox proportional hazards model demonstrated that TP53 mutations were independent predictors of OS rates for EACSCC patients (P = 0.007). Conclusion This study has suggested that TP53 mutations have potential for use as a biomarker for identifying individuals at high risk of developing tumors and for predicting survival outcome in EACSCC. IHC staining for p53 might play a useful role as screening tool for detecting TP53 mutations in patients with EACSCC.

Details

Database :
OAIster
Notes :
application/pdf, application/vnd.openxmlformats-officedocument.spreadsheetml.sheet, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1409766704
Document Type :
Electronic Resource